Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer

Seminars in Oncology

Volumn 42, Issue , 2015, Pages S11-S18

  Garon, Edward B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; DOCETAXEL; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MONOTHERAPY; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PROCEDURES; TRENDS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84944722612     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.09.019     Document Type: Review

References (40)

1. J.P. Dutcher Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma Oncology (Williston Park) 16 11 suppl 13 2002 4 10
2. E. Jonasch, and F.G. Haluska Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities Oncologist 6 2001 34 55
3. C. Robert, J. Schachter, G.V. Long, and et al. KEYNOTE-006 Investigators. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2015 2521 2532
4. J.S. Weber, S.P. D'Angelo, D. Minor, and et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Lancet Oncol 164 2015 375 384
5. K.J. Kallen, and U. Gnad-Vogt NSCLC - immunogenic after all? J Thorac Dis 3 2011 79 81
6. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
7. P.S. Linsley, J.L. Greene, W. Brady, J. Bajorath, J.A. Ledbetter, and R. Peach Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors Immunity 1 1994 793 801
8. J.L. Riley, M. Mao, S. Kobayashi, and et al. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA 4 receptors Proc Natl Acad Sci U S A 99 2002 11790 11795
9. H. Schneider, J. Downey, A. Smith, and et al. Reversal of the TCR stop signal by CTLA 4 Science 313 2006 1972 1975
10. J.G. Egen, and J.P. Allison Cytotoxic T lymphocyte antigen 4 accumulation in the immunological synapse is regulated by TCR signal strength Immunity 16 2002 23 35
11. R.V. Parry, J.M. Chemnitz, K.A. Frauwirth, and et al. CTLA 4 and PD 1 receptors inhibit T cell activation by distinct mechanisms Mol. Cell Biol 25 2005 9543 9553
12. E.B. Garon, N.A. Rizvi, R. Hui, et al.; ?>for the KEYNOTE-001 Investigators Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2015 2018 2028
13. A. Daud, A. Ribas, C. Robert, and et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001 J Clin Oncol 33 suppl 2015 Abstract 9005
14. S.L. Topalian, M. Sznol, D.F. McDermott, and et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 2014 1020 1030
15. M.A. Postow, M.K. Callahan, and J.D. Wolchok Immune checkpoint blockade in cancer therapy J Clin Oncol 33 2015 1974 1982
16. S.N. Gettinger, L. Horn, L. Gandhi, and et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 33 2015 2004 2012
17. A.I. Spira, K. Park, J. Mazieres, and et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A v docetaxel in 2L/3L NSCLC (POPLAR) J Clin Oncol 33 suppl 2015 Abstract 8010
18. N.A. Rizvi, J. Mazières, D. Planchard, and et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Lancet Oncol 16 2015 257 265
19. J. Brahmer, K.L. Reckamp, P. Baas, and et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 2015 123 135
20. L. Paz-Ares, L. Horn, H. Borghaei, and et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC) J Clin Oncol 33 suppl 2015 Abstract LBA109
21. ®): non-small cell lung cancer. Version 6.2015. Available at http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed June 11, 2015.
22. Bristol-Myers Squibb [press release]. CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early. April 17, 2015. Available at: http://news.bms.com/press-release/checkmate-057-pivotal-phase-iii-opdivo-nivolumab-lung-cancer-trial-stopped-early. Accessed June 3, 2015.
23. L. Horn, D.R. Spigel, S.N. Gettinger, and et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study J Clin Oncol 33 suppl 2015 Abstract 8029
24. N.A. Rizvi, J.R. Brahmer, S.H. Ou, and et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) J Clin Oncol 33 suppl 2015 Abstract 8032
25. D.R. Spigel, N. Scott, S.N. Gettinger, and et al. Clinical activity, safety, and biomarkers of PD-L1 blockade of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol 31 suppl 2013 Abstract 8008
26. J.R. Brahmer, N.A. Rizvi, J. Lutzky, and et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC J Clin Oncol 32 suppl 2014 Abstract 8021
27. R.S. Herbst, J.C. Soria, M. Kowanetz, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
28. N.A. Rizvi, M.D. Hellmann, A. Snyder, and et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science 348 2015 124 128
29. M. Howell, R. Lee, S. Bowyer, A. Fusi, and P. Lorigan Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer Lung Cancer 88 2015 117 123
30. J.D. Wolchok, and Y. Saenger The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation Oncologist 13 suppl 4 2008 2 9
31. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
32. C. Robert, L. Thomas, I. Bondarenko, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
33. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
34. J.L. Gulley, D. Spigel, K. Kelly, and et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy J Clin Oncol 33 suppl 2015 Abstract 8034
35. P. Zatloukal, D.S. Heo, K. Park, and et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) J Clin Oncol 27 15s 2009 Abstract 8071
36. T.J. Lynch, I. Bondarenko, A. Luft, and et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study J Clin Oncol 30 2012 2046 2054
37. S.J. Antonia, S.B. Goldberg, A.S. Balmanoukian, and et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC J Clin Oncol 33 suppl 2015 Abstract 3014
38. G.R. Oxnard, S.S. Ramalingam, M.-J. Ahn, and et al. Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer J Clin Oncol 33 suppl 2015 Abstract 2509
39. B.C. Creelan, L.Q. Chow, D.-W. Kim, S.-E. Kim, T. Yeh, J.J. Karakunnel, and et al. Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC) J Clin Oncol 33 suppl 2015 Abstract 3047
40. S.V. Liu, J.D. Powderly, D.R. Camidge, and et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) J Clin Oncol 33 suppl 2015 Abstract 8030